Patents Assigned to Navinta LLC
-
Patent number: 11826466Abstract: A ready to use or ready to dilute for use, stable liquid Bendamustine solution formed of 90 to about 200 mg/mL Bendamustine Hydrochloride or a hydrate form thereof, and a co-solvent consisting of 1% v/v to 12% v/v water and 88% v/v to 99% v/v N,N-Dimethylacetamide (DMA). The liquid Bendamustine solution is room-temperature stable for at least 90 days. Optionally, 0.01 to about 0.5 mg/mL antioxidant, preferably, butylated hydroxytoluene is included in the solution.Type: GrantFiled: December 3, 2020Date of Patent: November 28, 2023Assignee: Navinta, LLCInventor: Mahendra R. Patel
-
Patent number: 11760730Abstract: An improved process for the preparation of high purity Levosimendan includes treatment of Levosimendan crude with an organic acid, adding an organic acid to precipitate Levosimendan and isolating pure Levosimendan from the precipitate. Levosimendan obtained by the improved process is pharmaceutically acceptable with no impurity higher than 0.2 percent.Type: GrantFiled: January 10, 2022Date of Patent: September 19, 2023Assignee: Navinta, LLCInventors: Chiragkumar Anilkumar Bhatt, Keyurkumar Amrutla Pandya, Pankaj Vasudev Parmar, John Muthiah Raja Jeyakumar
-
Patent number: 10905677Abstract: Liquid pharmaceutical formulation of Bendamustine that include bendamustine active pharmaceutical ingredient, N,N-Dimethylacetamide, and water in an amount of about 0.3% to 40%. The active pharmaceutical ingredient is Bendamustine, a pharmaceutically acceptable salt, and/or a hydrate form thereof, preferably Bendamustine HCl monohydrate. The formulations contain 20-200 mg/mL Bendamustine. The formulations are stable upon long term storage at refrigerated conditions. They can be administered to treat neoplastic conditions without reconstituting prior to administration.Type: GrantFiled: August 29, 2017Date of Patent: February 2, 2021Assignee: Navinta, LLCInventor: Mahendra R. Patel
-
Patent number: 10544175Abstract: Dicyclohexylamine salt of fosaprepitant (fosaprepitant DCHA), a process for preparing fosaprepitant DCHA, and a use of fosaprepitant DCHA in the preparation of pharmaceutically acceptable fosaprepitant dimeglumine with high purity is provided. Fosaprepitant dimeglumine is prepared by treating fosaprepitant DCHA with an acid to form fosaprepitant, followed by adding N-methyl-D-glucamine to fosaprepitant.Type: GrantFiled: October 10, 2017Date of Patent: January 28, 2020Assignee: Navinta, LLCInventors: Jigneshkumar Jasubhai Patel, Raja Jeyakumar John Muthiah
-
Patent number: 10456418Abstract: The present invention provides a method for designing a ferric pyrophosphate citrate complex composition containing pyrophosphate, citrate, ferric, sodium, and sulfate ions and calculating and adjusting each salt needed based on a choice of salts that contain the above ions and a desired concentration of each ion in the final product. The present invention also provides a process for preparing a pharmaceutical dosage form of ferric pyrophosphate citrate complex composition in liquid form which is ready to be administrated to patients in need and which maintains the mass balance of ion sources throughout the process.Type: GrantFiled: October 5, 2016Date of Patent: October 29, 2019Assignee: Navinta, LLCInventors: Mahendra R. Patel, Shrenik K. Shah
-
Patent number: 10064826Abstract: The invention provides a process for preparing stable, high API content, solid pharmaceutical dosage forms by direct compression or dry granulation, characterized in that the pharmaceutical tablets rapidly disintegrate in water or other aqueous solutions to produce a clear or almost clear solution. Also provided is a pharmaceutical carglumic acid tablet, which has improved manufacturing, dissolution, and stability properties, and is less expensive to produce, compared to the equivalent commercial product.Type: GrantFiled: March 14, 2014Date of Patent: September 4, 2018Assignee: Navinta, LLCInventors: Sanjay Rangnathrao Kawale, Mahendra R. Patel
-
Patent number: 9850267Abstract: The present invention provides dicyclohexylamine salt of fosaprepitant (fosaprepitant DCHA), a process for preparing fosaprepitant DCHA, and a use of fosaprepitant DCHA in the preparation of pharmaceutically acceptable fosaprepitant dimeglumine with high purity. Fosaprepitant dimeglumine is prepared by treating fosaprepitant DCHA with an acid to form fosaprepitant, followed by adding N-methyl-D-glucamine to fosaprepitant.Type: GrantFiled: May 26, 2016Date of Patent: December 26, 2017Assignee: Navinta, LLCInventors: Jigneshkumar Jasubhai Patel, Raja Jeyakumar John Muthiah
-
Patent number: 9718777Abstract: A process for the preparation and isolation of crystalline miglustat without the use of a column chromatography or ion exchange purification. The crystalline miglustat has a high purity and a melting point of 128° C. and an endothermic peak is 133° C.Type: GrantFiled: December 10, 2015Date of Patent: August 1, 2017Assignee: Navinta, LLCInventors: Shrenik K. Shah, Raju Mahadev Kharatkar, Chiragkumar Anilkumar Bhatt, Jitendra Bhagwandas Kevat
-
Patent number: 9603930Abstract: The present invention provides stable bendamustine-containing pharmaceutical compositions suitable for long term storage. The compositions include bendamustine, a pharmaceutically acceptable salt, and/or a hydrate form thereof, a solvent mixture of N,N-dimethylacetamide and glycerin, and an antioxidant. The bendamustine-containing compositions have less than about 2% of total impurities after two month storage at 25° C./60% RH. The pharmaceutical compositions may be used for treating neoplastic diseases.Type: GrantFiled: December 4, 2015Date of Patent: March 28, 2017Assignee: Navinta, LLCInventor: Mahendra R. Patel
-
Patent number: 9475891Abstract: A novel process of manufacturing colesevelam hydrochloride including the steps of alkylating polyallylamine with n-decylbromide and 6-bromohexyl trimethyl ammonium bromide, followed by cross-linking the alkylated polyallylamine with epichlorohydrin in an aqueous medium, and adding a suitable chloride ion source to obtain colesevelam hydrochloride.Type: GrantFiled: September 18, 2014Date of Patent: October 25, 2016Assignee: Navinta, LLCInventor: Mahendra R. Patel
-
Patent number: 8575385Abstract: This invention provides a process of making optically pure melphalan of the formula by hydroxyethylation, in a regioselective manner, of the aromatic amino group rather than the glycinic amino group.Type: GrantFiled: March 20, 2009Date of Patent: November 5, 2013Assignee: Navinta LLCInventors: Christopher N. Jobdevairakkam, Hero Velladurai
-
Patent number: 8404784Abstract: A novel process of manufacturing sevelamer carbonate from a polyallylamine carbonate or bicarbonate chloride salt. Process for manufacture of carbonate and/or bicarbonate salts of water insoluble polymers containing amino groups that are useful as anion binders in the gastrointestinal (GI) system. The process arranges the polyallylamine chain in a solution in such a way that the cross-linking reaction with epichlorohydrin can be controlled at a desired reaction rate.Type: GrantFiled: December 2, 2009Date of Patent: March 26, 2013Assignee: Navinta LLCInventors: Christopher N. Jobdevairakkam, Hero Velladurai
-
Patent number: 7884227Abstract: A synthesis and purification of felbamate, an anticonvulsant, are provided. The product of the synthesis and purification is with high untapped and tapped bulk densities, which increase ease of handling and suitability for use in pharmaceutical formulations. The felbamate may be incorporated into pharmaceutical compositions that can be administered orally for treatment of epilepsy.Type: GrantFiled: October 27, 2008Date of Patent: February 8, 2011Assignee: Navinta LLCInventors: Christopher Newton Jobdevairakkam, Hero Velladurai
-
Patent number: 7807830Abstract: The present invention provides an improved process of preparing hydralazine hydrochloride, which involves the preparation of 1-chlorophthalazine salt and further reacting with hydrazine followed by purification of hydralazine hydrochloride, which is free of phosphate, does not contain any individual impurities more than 0.05%, total impurities less than 0.5%, and a hydrazine content of not more than 0.001%, and preferably less than 0.0003%. One benefit of improved purity is enhanced storage stability.Type: GrantFiled: April 3, 2009Date of Patent: October 5, 2010Assignee: Navinta LLCInventors: Christopher N. Jobdevairakkam, Jayaraman Kannappan, Jagadeesh B. Rangisetty
-
Patent number: 7683175Abstract: The present invention describes a novel process of preparation of optically pure L-Pipecolic acid and an improved process for the conversion of L-pipecolic acid to L-N-(2,6-dimethylphenyl)-1-propyl-2-piperidinocarboxamide, its hydrochloride salt and hydrochloride monohydrate.Type: GrantFiled: February 9, 2006Date of Patent: March 23, 2010Assignee: Navinta, LLCInventors: Jagadeesh B. Rangisetty, Manik R. Pullagurla, Raja J. J. Muthiah, Christopher N. Jobdevairakkam
-
Patent number: 7674780Abstract: A process is provided for preparing an iron sucrose complex, substantially free of excipients, for providing an iron sucrose complex co-precipitated with sucrose, and for providing iron sucrose complexes in aqueous solution.Type: GrantFiled: July 12, 2004Date of Patent: March 9, 2010Assignee: Navinta LLCInventors: Christopher Benny Newton, Jagadeesh Babu Rangisetty
-
Patent number: 7585978Abstract: A process of preparing a stable parenteral solution of a 1,4-dihydropyridine salt, such as nicardipine hydrochloride, in an acidic aqueous medium. The presence of L-arginine in the solution enhances the solubility of the salt, which is poorly soluble in water. An aqueous, injectable isotonic solution at pH about 3.5-3.6 consists essentially of nicardipine hydrochloride, L-arginine, and a sugar alcohol. An improved single pot manufacturing process for obtaining unsymmetrical 1,4-dihydropyridines by using more than one mole equivalent of aldehyde with respect to the other reactants (amino crotonate and acetoacetate ester). The reaction can be conducted in a solvent present at 20 times the amount of any one component. A process for changing one polymorph of nicardipine hydrochloride (Form A) into another (Form B), and a separate process for the reverse (Form B into Form A).Type: GrantFiled: November 28, 2006Date of Patent: September 8, 2009Assignee: Navinta LLCInventors: Christopher N. Jobdevairakkam, Jayaraman Kannappan
-
Publication number: 20090187018Abstract: The present invention provides an improved process of preparing hydralazine hydrochloride, which involves the preparation of 1-chlorophthalazine salt and further reacting with hydrazine followed by purification of hydralazine hydrochloride, which is free of phosphate, does not contain any individual impurities more than 0.05%, total impurities less than 0.5%, and a hydrazine content of not more than 0.001 %, and preferably less than 0.0003%. One benefit of improved purity is enhanced storage stability.Type: ApplicationFiled: April 3, 2009Publication date: July 23, 2009Applicant: Navinta LLCInventors: Christopher N. Jobdevairakkam, Jayaraman Kannappan, Jagadeesh B. Rangisetty
-
Patent number: 7531653Abstract: The present invention provides an improved process of preparing hydralazine hydrochloride, which involves the preparation of 1-chlorophthalazine salt and further reacting with hydrazine followed by purification of hydralazine hydrochloride, which is free of phosphate, does not contain any individual impurities more than 0.05%, total impurities less than 0.5%, and a hydrazine content of not more than 0.001%, and preferably less than 0.0003%. One benefit of improved purity is enhanced storage stability.Type: GrantFiled: December 7, 2005Date of Patent: May 12, 2009Assignee: Navinta LLCInventors: Jagadeesh B. Rangisetty, Christopher N. Jobdevairakkam, Jayaraman Kannappan
-
Publication number: 20090111871Abstract: A synthesis and purification of felbamate, an anticonvulsant, are provided. The product of the synthesis and purification is with high untapped and tapped bulk densities, which increase ease of handling and suitability for use in pharmaceutical formulations. The felbamate may be incorporated into pharmaceutical compositions that can be administered orally for treatment of epilepsy.Type: ApplicationFiled: October 27, 2008Publication date: April 30, 2009Applicant: NAVINTA LLCInventors: Christopher Newton Jobdevairakkam, Hero Velladurai